Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 prevents CCl4-induced liver cirrhosis by protecting the intestinal barrier in rats

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Shi, Ding ^a   Lv, Longxian ^a   Fang, Daiqiong ^a   Wu, Wenrui ^a   Hu, Chenxia ^a   Xu, Lichen ^a   Chen, Yanfei ^a   Guo, Jing ^a   Hu, Xinjun ^a   Li, Ang ^a   Guo, Feifei ^a   Ye, Jianzhong ^a   Li, Yating ^a   Andayani, Dewi ^a   Li, Lanjuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; CYTOKINE; ENDOTOXIN; PROBIOTIC AGENT; RNA 16S;

ANIMAL; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; INTESTINE FLORA; INTESTINE MUCOSA; LACTOBACILLUS SALIVARIUS; LIVER CIRRHOSIS; METABOLISM; MICROBIOLOGY; PEDIOCOCCUS PENTOSACEUS; PHYSIOLOGY; RAT; ULTRASTRUCTURE;

ANIMALS; CARBON TETRACHLORIDE; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTOXINS; GASTROINTESTINAL MICROBIOME; GENE EXPRESSION REGULATION; INTESTINAL MUCOSA; LACTOBACILLUS SALIVARIUS; LIVER CIRRHOSIS; PEDIOCOCCUS PENTOSACEUS; PROBIOTICS; RATS; RNA, RIBOSOMAL, 16S;

EID: 85026661155     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-07091-1     Document Type: Article

References (43)

1. Tsochatzis, E. A., Bosch, J. & Burroughs, A. K. Liver cirrhosis. Lancet 383, 1749-1761, doi:10.1016/s0140-6736(14)60121-5 (2014).
2. Chen, Y. et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54, 562-572, doi:10.1002/hep.24423 (2011).
3. Lu, H. et al. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb. Ecol. 61, 693-703, doi:10.1007/s00248-010-9801-8 (2011).
4. Lv, L. X. et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ. Microbiol. 18, 2272-2286, doi:10.1111/1462-2920.13401 (2016).
5. Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59-64, doi:10.1038/nature13568 (2014).
6. Chen, Y. et al. Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis. BMC Genomics 15, 753, doi:10.1186/1471-2164-15-753 (2014).
7. Ahluwalia, V. et al. Impaired gut-liver-brain axis in patients with cirrhosis. Sci. Rep. 6, 26800, doi:10.1038/srep26800 (2016).
8. Lv, L. X. et al. Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 improves acute liver injury induced by D-galactosamine in rats. Applied microbiology and biotechnology 98, 5619-5632, doi:10.1007/s00253-014-5638-2 (2014).
9. Seo, M. et al. Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats. Dig. Dis. Sci. 58, 3534-3544, doi:10.1007/s10620-013-2879-3 (2013).
10. Yeon, S. J., Kim, S. K., Kim, J. M., Lee, S. K. & Lee, C. H. Effects of fermented pepper powder on body fat accumulation in mice fed a high-fat diet. Biosci. Biotechnol. Biochem. 77, 2294-2297, doi:10.1271/bbb.130063 (2013).
11. Forsyth, C. B. et al. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 43, 163-172, doi:10.1016/j.alcohol.2008.12.009 (2009).
12. Johansson, M. E. et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 63, 281-291, doi:10.1136/gutjnl-2012-303207 (2014).
13. Xing, H. C. et al. Protective role of supplement with foreign Bifidobacterium and Lactobacillus in experimental hepatic ischemiareperfusion injury. J Gastroenterol Hepatol 21, 647-656, doi:10.1111/j.1440-1746.2006.04306.x (2006).
14. Fu, L., Niu, B., Zhu, Z., Wu, S. & Li, W. CD-HIT: accelerated for clustering the next-generation sequencing data. Bioinformatics 28, 3150-3152, doi:10.1093/bioinformatics/bts565 (2012).
15. Wang, Q., Garrity, G. M., Tiedje, J. M. & Cole, J. R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl. Environ. Microbiol. 73, 5261-5267, doi:10.1128/AEM.00062-07 (2007).
16. Heymann, F., Trautwein, C. & Tacke, F. Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm. Allergy Drug Targets 8, 307-318 (2009).
17. D'Argenio, G. et al. Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage? Liver Int. 33, 687-697, doi:10.1111/liv.12117 (2013).
18. Sanchez, E. et al. VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Liver Int. 35, 735-745, doi:10.1111/liv.12566 (2015).
19. Tsukamoto, H. Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcohol Clin. Exp. Res. 23, 911-916 (1999).
20. Seo, W. et al. Exosome-mediated activation of toll-like receptor 3 in stellate cells stimulates interleukin-17 production by gammadelta T cells in liver fibrosis. Hepatology 64, 616-631, doi:10.1002/hep.28644 (2016).
21. Wiest, R., Lawson, M. & Geuking, M. Pathological bacterial translocation in liver cirrhosis. J. Hepatol. 60, 197-209, doi:10.1016/j. jhep.2013.07.044 (2014).
22. Seki, E. & Schwabe, R. F. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology 61, 1066-1079, doi:10.1002/hep.27332 (2015).
23. Hartmann, P., Haimerl, M., Mazagova, M., Brenner, D. A. & Schnabl, B. Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology 143(1330-1340), e1331, doi:10.1053/j. gastro.2012.07.099 (2012).
24. Gewirtz, A. T., Navas, T. A., Lyons, S., Godowski, P. J. & Madara, J. L. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol. 167, 1882-1885, doi:10.4049/jimmunol.167.4.1882 (2001).
25. Miura, K. et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139, 323-334 e327, doi:10.1053/j.gastro.2010.03.052 (2010).
26. Hemmann, S., Graf, J., Roderfeld, M. & Roeb, E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J. Hepatol. 46, 955-975, doi:10.1016/j.jhep.2007.02.003 (2007).
27. Tsiaoussis, G. I., Assimakopoulos, S. F., Tsamandas, A. C., Triantos, C. K. & Thomopoulos, K. C. Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications. World J. Hepatol. 7, 2058-2068, doi:10.4254/wjh.v7. i17.2058 (2015).
28. Ubeda, M. et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J. Hepatol. 64, 1049-1057, doi:10.1016/j.jhep.2015.12.010 (2016).
29. Bellot, P., Frances, R. & Such, J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int. 33, 31-39, doi:10.1111/liv.12021 (2013).
30. Lata, J., Jurankova, J., Kopacova, M. & Vitek, P. Probiotics in hepatology. World J. Gastroenterol. 17, 2890-2896, doi:10.3748/wjg.v17. i24.2890 (2011).
31. Simeoli, R. et al. Preventive and therapeutic effects of Lactobacillus paracasei B21060-based synbiotic treatment on gut inflammation and barrier integrity in colitic mice. J. Nutr. 145, 1202-1210, doi:10.3945/jn.114.205989 (2015).
32. De Angelis, M. et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PloS one 9, e99006, doi:10.1371/journal.pone.0099006 (2014).
33. Dinh, D. M. et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J. Infect. Dis. 211, 19-27, doi:10.1093/infdis/jiu409 (2015).
34. Molina, J., Barrantes, G., Quesada-Gomez, C., Rodriguez, C. & Rodriguez-Cavallini, E. Phenotypic and genotypic characterization of multidrug-resistant Bacteroides, Parabacteroides spp., and Pseudoflavonifractor from a Costa Rican hospital. Microb. Drug Resist. 20, 478-484, doi:10.1089/mdr.2013.0180 (2014).
35. Cani, P. D. & Delzenne, N. M. The role of the gut microbiota in energy metabolism and metabolic disease. Curr. Pharm. Des. 15, 1546-1558 (2009).
36. Yang, T. et al. Gut dysbiosis is linked to hypertension. Hypertension 65, 1331-1340, doi:10.1161/HYPERTENSIONAHA.115.05315 (2015).
37. Sanz, Y. & Moya-Perez, A. Microbiota, inflammation and obesity. Adv Exp Med Biol 817, 291-317, doi:10.1007/978-1-4939-0897-4-14 (2014).
38. Kovatcheva-Datchary, P. et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of prevotella. Cell Metab. 22, 971-982, doi:10.1016/j.cmet.2015.10.001 (2015).
39. Geissinger, O., Herlemann, D. P., Morschel, E., Maier, U. G. & Brune, A. The ultramicrobacterium "Elusimicrobium minutum" gen. nov., sp. nov., the first cultivated representative of the termite group 1 phylum. Appl. Environ. Microbiol. 75, 2831-2840, doi:10.1128/AEM.02697-08 (2009).
40. Lam, Y. Y. et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One 7, e34233, doi:10.1371/journal.pone.0034233 (2012).
41. Quigley, E. M., Stanton, C. & Murphy, E. F. The gut microbiota and the liver. Pathophysiological and clinical implications. J. Hepatol. 58, 1020-1027, doi:10.1016/j.jhep.2012.11.023 (2013).
42. Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541-546, doi:10.1038/nature12506 (2013).
43. Chen, Y. et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J. Gastroenterol. Hepatol. 30, 1429-1437, doi:10.1111/jgh.12932 (2015).